Barriers and Best Practices on the Management of Opioid Use Disorder

References

• Nelson LS, Olsen D. Opioids. In: Nelson LS, Howland MA, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS, eds. Goldfrank’s Toxicologic Emergencies, 11e. New York, NY: McGraw-Hill; 2019. https://accesspharmacy.mhmedical.com. Accessed August 29, 2023.
   Google Scholar
• Kerrigan S, Goldberger BA. Opioids. In: Levine BS, Kerrigan S, eds. Principles of Forensic Toxicology. 5th ed. Switzerland: Springer Nature Switzerland AG; 2020:347–369.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. 2022. Key Substance Use and Mental Health Indicators in the United States: Results from the 2021 National Survey on Drug Use and Health. (HHS Publication No. PEP22-07-01-005, NSDUH Series H-57). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report. Accessed August 29, 2023.
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013. https://www.asam.org/docs/default-source/education-docs/dsm-5-dx-oud-8-28-2017.pdf?sfvrsn=70540c2_2#:∼:text=Diagnostic%20Criteria*&text=There%20is%20a%20persistent%20desire,strong%20desire%20to%20use%20opioids. Accessed January 10, 2023.
   Google Scholar
• Cragg A, Hau JP, Woo SA, Kitchen SA, Liu C, Doyle-Waters MM, Hohl CM. Risk factors for misuse of prescribed opioids: a systematic review and meta-analysis. Ann Emerg Med. 2019;74(5):634–46. doi:10.1016/j.annemergmed.2019.04.019.
   PubMed Web of Science ®Google Scholar
• Palamar JJ, Cottler LB, Goldberger BA, Severtson SG, Grundy DJ, Iwanicki JL, Ciccarone D. Trends in characteristics of fentanyl-related poisonings in the United States, 2015-2021. Am J Drug Alcohol Abuse. 2022;48(4):471–80. doi:10.1080/00952990.2022.2081923.
   PubMed Web of Science ®Google Scholar
• Webster LR. Risk factors for opioid-use disorder and overdose. Anesth Analg. 2017;125(5):1741–8. doi:10.1213/ANE.0000000000002496.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Synthetic opioid overdose data. https://www.cdc.gov/drugoverdose/deaths/synthetic/index.html#print. Accessed January 10, 2023.
   Google Scholar
• Centers for Disease Control and Prevention. Opioid data analysis and resources. https://www.cdc.gov/opioids/data/analysis-resources.html. Accessed June 23, 2023.
   Google Scholar
• Centers for Disease Control and Prevention. U.S. overdose deaths in 2021 increased half as much as in 2020 – but are still up 15%. National Center for Health Statistics. May 11, 2022. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/202205.htm#print. Accessed January 9, 2023.
   Google Scholar
• Reichle CW, Smith GM, Gravenstein JS, Macris SG, Beecher HK. Comparative analgesic potency of heroin and morphine in postoperative patients. J Pharmacol Exp Ther. 1962;136(1):43–6.
   PubMed Web of Science ®Google Scholar
• Rook EJ, van Ree JM, van den Brink W, Hillebrand MJX, Huitema ADR, Hendriks VM, Beijnen JH. Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. Basic Clin Pharmacol Toxicol. 2006;98(1):86–96. doi:10.1111/j.1742-7843.2006.pto_233.x.
   PubMed Web of Science ®Google Scholar
• Sporer KA. Acute heroin overdose. Ann Intern Med. 1999;130(7):584–90. doi:10.7326/0003-4819-130-7-199904060-00019.
   PubMed Web of Science ®Google Scholar
• Ahmad FC, Rossen LM, Sutton P. Provisional drug overdose death counts. Atlanta, GA: National Center for Health Statistics; 2023.
   Google Scholar
• Wide-Ranging Online Data for Epidemiologic Research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics; 2022. http://wonder.cdc.gov.
   Google Scholar
• Centers for Disease Control and Prevention. Fentanyl Facts. https://www.cdc.gov/stopoverdose/fentanyl/index.html#print. Accessed January 10, 2023.
   Google Scholar
• Gladden RM, O'Donnell J, Mattson CL, Seth P. Changes in opioid-involved overdose deaths by opioid type and presence of benzodiazepines, cocaine, and methamphetamine—25 States, July–December 2017 to January–June 2018. MMWR Morb Mortal Wkly Rep. 2019;68(34):737–44. doi:10.15585/mmwr.mm6834a2.
   PubMed Web of Science ®Google Scholar
• Lexicomp Online. Lexi-Drugs. Fentanyl. Waltham, MA: UpToDate, Inc. http://online.lexi.com. Accessed January 10, 2023.
   Google Scholar
• Comer SD, Cahill CM. Fentanyl: receptor pharmacology, abuse potential, and implications for treatment. Neurosci Biobehav Rev. 2019;106:49–57. doi:10.1016/j.neubiorev.2018.12.005.
   PubMed Web of Science ®Google Scholar
• United States Drug Enforcement Administration (DEA). DEA Issues Carfentanil Warning to Police and Public. September 22, 2016. https://www.dea.gov/press-releases/2016/09/22/dea-issues-carfentanil-warning-police-and-public. Accessed January10, 2023.
   Google Scholar
• Sufentanil [Package Insert]. Lake Forest, IL: Akorn, Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019050s032lbl.pdf. Accessed June 22, 2023.
   Google Scholar
• Stemrich RA, Weber JV, McCall KL, Piper BJ. Pronounced declines in dispensed licit fentanyl, but not fentanyl derivatives. Res Social Adm Pharm. 2022;18(6):3046–51. doi:10.1016/j.sapharm.2021.08.001.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. 2020. Medications for Opioid Use Disorder for Healthcare and Addiction Professionals, Policymakers, Patients, and Families. Treatment Improvement Protocol TIP 63 (HHS Publication No. PEP20-02-01-006). Rockville, MD: US Department of Health and Human Services. https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document/PEP20-02-01-006. Accessed January 10, 2023.
   Google Scholar
• Palamar JJ, Ciccarone D, Rutherford C, Keyes KM, Carr TH, Cottler LB. Trends in seizures of powders and pills containing illicit fentanyl in the United States, 2018 through 2021. Drug Alcohol Depend. 2022;234:109398. doi:10.1016/j.drugalcdep.2022.109398.
   PubMed Web of Science ®Google Scholar
• Biden-Harris Administration Designates Fentanyl Combined with Xylazine as an Emerging Threat to the United States. https://www.whitehouse.gov/ondcp/briefing-room/2023/04/12/biden-harris-administration-designates-fentanyl-combined-with-xylazine-as-an-emerging-threat-to-the-united-states/. Accessed July 21, 2023.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Illicitly manufactured fentanyl–involved overdose deaths with detected xylazine—United States, January 2019–June 2022. Morbidity Mortality Wkly Rep. 2023;72(26):721–7.
   PubMed Web of Science ®Google Scholar
• Alexander RS, Canver BR, Sue KL, Morford KL. Xylazine and overdoses: trends, concerns, and recommendations. Am J Public Health. 2022;112(8):1212–6. doi:10.2105/AJPH.2022.306881.
   PubMed Web of Science ®Google Scholar
• Malayala SV, Papudesi BN, Bobb R, Wimbush A. Xylazine-induced skin ulcers in a person who injects drugs in Philadelphia, Pennsylvania, USA. Cureus. 2022;14(8):e28160. doi:10.7759/cureus.28160.
   PubMed Web of Science ®Google Scholar
• American Society of Addiction Medicine. National Practice Guideline. For the Treatment of Opioid Use Disorder. 2020 Focused Update. https://sitefinitystorage.blob.core.windows.net/sitefinity-production-blobs/docs/default-source/guidelines/npg-jam-supplement.pdf?sfvrsn=a00a52c2_2. Accessed January 10, 2023.
   Google Scholar
• Lexicomp Online. Lexi-Drugs. Naloxone. Waltham, MA: UpToDate, Inc. http://online.lexi.com. Accessed January 10, 2023.
   Google Scholar
• Silverstein SM, Daniulaityte R, Martins SS, Miller SC, Carlson RG. Everything is not right anymore": buprenorphine experiences in an era of illicit fentanyl. Int J Drug Policy. 2019;74:76–83. doi:10.1016/j.drugpo.2019.09.003.
   PubMed Web of Science ®Google Scholar
• Narcan [Package Insert]. Plymouth Meeting, PA: Adapt Pharma, Inc.; August, 2020. https://www.narcan.com/wp-content/uploads/2022/06/Gen2-Prescribing-Information.pdf. Accessed January 10, 2023.
   Google Scholar
• Kloxxado [Package Insert]. Columbus, OH: Hikma Specialty USA, Inc.; April, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212045s000lbl.pdf. Accessed January 10, 2023.
   Google Scholar
• Zimhi [Package Insert]. San Diego, CA: Adamis Pharmaceuticals Corporation; October 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212854s000lbl.pdf. Accessed January 11, 2023.
   Google Scholar
• Opvee [Package Insert]. Santa Monica, CA: Opiant Pharmaceuticals; May, 2023. https://opvee.com/wp-content/uploads/2023/05/Combined_USPI-Patient-Info-IFU_May-22-2023.pdf. Accessed June 19, 2023.
   Google Scholar
• Krieter P, Gyaw S, Crystal R, Skolnick P. Fighting fire with fire: development of intranasal nalmefene to treat synthetic opioid overdose. J Pharmacol Exp Ther. 2019;371(2):409–15. doi:10.1124/jpet.118.256115.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. Naloxone: The Opioid Reversal Drug That Saves Lives. How Healthcare Providers and Patients Can Better Utilize This Life-Saving Drug. https://www.hhs.gov/opioids/sites/default/files/2018-12/naloxone-coprescribing-guidance.pdf. Accessed January 11, 2023.
   Google Scholar
• United States Food and Drug Administration (FDA). Drug Safety Communications. FDA Identifies Harm Reported from Sudden Discontinuation of Opioid Pain Medicines and Requires Label Changes to Guide Prescribers on Gradual, Individualized Tapering. April 9, 2019. https://www.fda.gov/media/122935/download. Accessed January 11, 2023.
   Google Scholar
• Herring AA, Perrone J, Nelson LS. Managing opioid withdrawal in the emergency department with buprenorphine. Ann Emerg Med. 2019;73(5):481–7. doi:10.1016/j.annemergmed.2018.11.032.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Use of Medication-Assisted Treatment in Emergency Departments. HHS Publication No. PEP21-PL-Guide-5. Rockville, MD: National Mental Health and Substance Use Policy Laboratory. Substance Abuse and Mental Health Services Administration; 2021. https://store.samhsa.gov/sites/default/files/pep21-pl-guide-5.pdf. Accessed January 5, 2023.
   Google Scholar
• Vivitrol [Package Insert]. Waltham MA: Alkermes, Inc.; September, 2022. https://www.vivitrol.com/content/pdfs/prescribing-information.pdf. Accessed January 11, 2023.
   Google Scholar
• Sublocade [Package Insert]. North Chesterfield, VA: Indivior Inc.; August, 2022. https://www.sublocade.com/Content/pdf/prescribing-information.pdf. Accessed January 11, 2023.
   Google Scholar
• Lexicomp Online. Lexi-Drugs. Methadone. Waltham, MA: UpToDate, Inc. http://online.lexi.com. Accessed January 11, 2023.
   Google Scholar
• Suboxone [Package Insert]. North Chesterfield, VA: Indivior Inc,. June, 2022. https://www.suboxone.com/pdfs/prescribing-information.pdf. Accessed January 17, 2023.
   Google Scholar
• Zubsolv [Package Insert]. Morristown, NJ: Orexo US, Inc.; June, 2022. https://www.suboxone.com/pdfs/prescribing-information.pdf. Accessed January 17, 2023.
   Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2014(2):CD002207. doi:10.1002/14651858.CD002207.pub4.
   PubMedGoogle Scholar
• Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, Azocar F, Sanghavi DM. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622. doi:10.1001/jamanetworkopen.2019.20622.
   PubMed Web of Science ®Google Scholar
• Titus-Lay EN, Jaynes HA, Tomaselli Muensterman E, Walroth TA, Ott CA, Desta Z, Williams G, Moe PR, Wilbrandt M, Tisdale JE. Methadone-associated QT interval prolongation in patients undergoing maintenance therapy in an urban opioid treatment program. Pharmacotherapy. 2021;41(3):238–46. doi:10.1002/phar.2498.
   PubMed Web of Science ®Google Scholar
• Lexicomp Online. Lexi-Drugs. Buprenorphine. Waltham, MA: UpToDate, Inc. http://online.lexi.com. Accessed January 11, 2023.
   Google Scholar
• Brixadi [Package Insert]. Plymouth Meeting, PA: Braeburn Inc.; May 2023. https://www.brixadi.com/pdfs/brixadi-prescribing-information.pdf. Accessed June 18, 2023.
   Google Scholar
• Khanna IK, Pillarisetti S. Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain. J Pain Res. 2015;8:859–70. doi:10.2147/JPR.S85951.
   PubMed Web of Science ®Google Scholar
• Gudin J, Fudin J. A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain. Pain Ther. 2020;9(1):41–54. doi:10.1007/s40122-019-00143-6.
   PubMed Web of Science ®Google Scholar
• Lexicomp Online. Lexi-Drugs. Buprenorphine and Naloxone. Waltham, MA: UpToDate, Inc. http://online.lexi.com. Accessed January 11, 2023.
   Google Scholar
• Blazes CK, Morrow JD. Reconsidering the usefulness of adding naloxone to buprenorphine. Front Psychiatry. 2020;11:549272. doi:10.3389/fpsyt.2020.549272.
   PubMed Web of Science ®Google Scholar
• Nasser AF, Heidbreder C, Liu Y, Fudala PJ. Pharmacokinetics of sublingual buprenorphine and naloxone in subjects with mild to severe hepatic impairment (Child-Pugh Classes A, B, and C), in hepatitis C virus-seropositive subjects, and in healthy volunteers. Clin Pharmacokinet. 2015;54(8):837–49. doi:10.1007/s40262-015-0238-6.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration (FDA). FDA Warns about Dental Problems with Buprenorphine Medicines Dissolved in the Mouth to Treat Opioid Use Disorder and Pain. January 12, 2022. https://www.fda.gov/media/155352/download. Accessed June 22, 2023.
   Google Scholar
• Greenwald MK, Comer SD, Fiellin DA. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Drug Alcohol Depend. 2014;144:1–11. doi:10.1016/j.drugalcdep.2014.07.035.
   PubMed Web of Science ®Google Scholar
• Grande LA, Cundiff D, Greenwald MK, Murray M, Wright TE, Martin SA. Evidence on buprenorphine dose limits: a review. J Addict Med. 2023;17(5):509–16. doi:10.1097/ADM.0000000000001189.
   PubMed Web of Science ®Google Scholar
• Murphy SM, McCollister KE, Leff JA, Yang X, Jeng PJ, Lee JD, Nunes EV, Novo P, Rotrosen J, Schackman BR. Cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone to prevent opioid relapse. Ann Intern Med. 2019;170(2):90–8. doi:10.7326/M18-0227.
   PubMed Web of Science ®Google Scholar
• D’Onofrio G, O’Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, Bernstein SL, Fiellin DA. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636–44. doi:10.1001/jama.2015.3474.
   PubMed Web of Science ®Google Scholar
• Hawk KF, D'Onofrio G, Chawarski MC, O'Connor PG, Cowan E, Lyons MS, Richardson L, Rothman RE, Whiteside LK, Owens PH, et al. Barriers and facilitators to clinician readiness to provide emergency department–initiated buprenorphine. JAMA Netw Open. 2020;3(5):e204561. doi:10.1001/jamanetworkopen.2020.4561.
   PubMed Web of Science ®Google Scholar
• Huhn AS, Hobelmann JG, Oyler GA, Strain EC. Protracted renal clearance of fentanyl in persons with opioid use disorder. Drug Alcohol Depend. 2020;214:108147. doi:10.1016/j.drugalcdep.2020.108147.
   PubMed Web of Science ®Google Scholar
• De Aquino JP, Parida S, Sofuoglu M. The pharmacology of buprenorphine microinduction for opioid use disorder. Clin Drug Investig. 2021;41(5):425–36. doi:10.1007/s40261-021-01032-7.
   PubMed Web of Science ®Google Scholar
• Quirk K, Stevenson M. Buprenorphine microdosing for the pain and palliative care clinician. J Palliat Med. 2022;25(1):145–54. doi:10.1089/jpm.2021.0378.
   PubMed Web of Science ®Google Scholar
• Moe J, Badke K, Pratt M, Cho RY, Azar P, Flemming H, Sutherland KA, Harvey B, Gurney L, Lockington J, et al. Microdosing and standard-dosing take-home buprenorphine from the emergency department: a feasibility study. J Am Coll Emerg Physicians Open. 2020;1(6):1712–22. doi:10.1002/emp2.12289.
   PubMedGoogle Scholar
• Krenz JR, Hayes BD, Wakeman SE, Martin A, Raja AS, White BA, Koehl JL. Continuation of outpatient buprenorphine therapy after dispensing Buprenorphine-Naloxone from the emergency department. Clin Toxicol. 2022;60(4):429–32. doi:10.1080/15563650.2021.1968421.
   PubMed Web of Science ®Google Scholar
• Center for Addiction Medicine and Policy. Buprenorphine cross-tapering using a low-dose (microdosing) Strategy. Penn Medicine 2022. [updated September 2022. Available from https://penncamp.org/wp-content/uploads/2023/02/Buprenorphine_Lowdose_induction_microdosing_Final_11.22-1.pdf.
   Google Scholar
• Crisanti AS, Earheart J, Deissinger M, Lowerre K, Salvador JG. Implementation challenges and recommendations for employing peer support workers in emergency departments to support patients presenting after an opioid-related overdose. Int J Environ Res Public Health. 2022;19(9):5276.
   PubMed Web of Science ®Google Scholar
• Samuels AE, Bernstein LS, Marshall DLB, Krieger M, Baird J, Mello JM. Peer navigation and take-home naloxone for opioid overdose emergency department patients: preliminary patient outcomes. J Subst Abuse Treat. 2018;94:29–34. doi:10.1016/j.jsat.2018.07.013.
   PubMed Web of Science ®Google Scholar
• Scheuermeyer FX, DeWitt C, Christenson J, Grunau B, Kestler A, Grafstein E, Buxton J, Barbic D, Milanovic S, Torkjari R, et al. Safety of a brief emergency department observation protocol for patients with presumed fentanyl overdose. Ann Emerg Med. 2018;72(1):1–8.e1. doi:10.1016/j.annemergmed.2018.01.054.
   PubMed Web of Science ®Google Scholar
• National Institute on Drug Abuse, National Institutes of Health, U.S. Department of Health and Human Services. Naloxone DrugFacts; 2022. https://nida.nih.gov/publications/drugfacts/naloxone. Accessed June 16, 2023.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. Removal of DATA Waiver (X-Waiver) Requirement. January 12, 2023. https://www.samhsa.gov/medication-assisted-treatment/removal-data-waiver-requirement. Accessed January 13, 2023.
   Google Scholar
• Kazerouni NJ, Irwin AN, Levander XA, Geddes J, Johnston K, Gostanian CJ, Mayfield BS, Montgomery BT, Graalum DC, Hartung DM, et al. Pharmacy-related buprenorphine access barriers: an audit of pharmacies in counties with a high opioid overdose burden. Drug Alcohol Depend. 2021;224:108729. doi:10.1016/j.drugalcdep.2021.108729.
   PubMed Web of Science ®Google Scholar
• Thakur T, Frey M, Chewning B. Pharmacist roles, training, and perceived barriers in naloxone dispensing: a systematic review. J Am Pharm Assoc. 2020;60(1):178–94. doi:10.1016/j.japh.2019.06.016.
   Google Scholar
• Coon SA, Hill LG, Hutchison RW, Arnold LM, Jarrett JB, Ottney AR, Oung AB, Painter NA, Smith MA, Stranges PM, et al. Mobilizing pharmacists to address the opioid crisis: a joint opinion of the ambulatory care and adult medicine practice and research networks of the American College of Clinical Pharmacy. J Am Coll Clin Pharm. 2020;3(8):1493–513. doi:10.1002/jac5.1331.
   Google Scholar
• Hanson KA, Smart MH, Mandava MR, Carkovic E, Aslamy M, Lee TA, Pickard AS. Pharmacists and naloxone: barriers to dispensing and effectiveness of an educational outreach program. J Am Pharm Assoc. 2023;63(2):608–13.e3. doi:10.1016/j.japh.2022.12.018.
   Google Scholar
• Hill LG, Light AE, Green TC, Burns AL, Zadeh PS, Freeman PR. Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: a national survey of community-based pharmacists. J Am Pharm Assoc. 2023;63(1):252–60. e6. doi:10.1016/j.japh.2022.08.017.
   Google Scholar
• Ostrach B, Hill L, Carpenter D, Pollini R. Addressing buprenorphine bottlenecks in the context of MAT Act implementation: a shared responsibility. J Am Pharm Assoc. 2023;63(4):1044–8.
   Google Scholar
• Actions of the March 15, 2021 Virtual House of Delegates. American Pharmacists Association. https://www.pharmacist.com/Portals/0/PDFS/HOD/March_15_2021_Virtual_HOD_Session_Actions_FINAL.pdf?ver=lxb_o_r0k5IG0UiHVosA_g%3d%3d. Accessed January 25, 2023.
   Google Scholar
• American Medical Association. Increasing availability of naloxone H-95.932. https://policysearch.ama-assn.org/policyfinder/detail/naloxone?uri=/AMADoc/HOD-95.932.xml. Accessed January 25, 2023.
   Google Scholar
• Alabkal RM, Medlinskiene K, Silcock J, Graham A. Impact of pharmacist-led interventions to improve clinical outcomes for adults with type 2 diabetes at risk of developing cardiovascular disease: a systematic review and meta-analysis. J Pharm Pract. 2022;36(4):888–99. doi:10.1177/08971900211064459.
   PubMed Web of Science ®Google Scholar
• Coutureau C, Slimano F, Mongaret C, Kanagaratnam L. Impact of pharmacists-led interventions in primary care for adults with type 2 diabetes on HbA1c levels: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19(6):3156.
   PubMed Web of Science ®Google Scholar
• Marcum ZA, Jiang S, Bacci JL, Ruppar TM. Pharmacist-led interventions to improve medication adherence in older adults: a meta-analysis. J Am Geriatr Soc. 2021;69(11):3301–11. doi:10.1111/jgs.17373.
   PubMed Web of Science ®Google Scholar
• Reeves L, Robinson K, McClelland T, Adedoyin CA, Broeseker A, Adunlin G. Pharmacist interventions in the management of blood pressure control and adherence to antihypertensive medications: a systematic review of randomized controlled trials. J Pharm Pract. 2021;34(3):480–92. doi:10.1177/0897190020903573.
   PubMed Web of Science ®Google Scholar
• Rodrigues CR, Harrington AR, Murdock N, Holmes JT, Borzadek EZ, Calabro K, Martin J, Slack MK. Effect of pharmacy-supported transition-of-care interventions on 30-day readmissions: a systematic review and meta-analysis. Ann Pharmacother. 2017;51(10):866–89. doi:10.1177/1060028017712725.
   PubMed Web of Science ®Google Scholar
• Mid-Level Practitioners Authorization by State. https://www.deadiversion.usdoj.gov/drugreg/practioners/mlp_by_state.pdf. Accessed January 25, 2022.
   Google Scholar
• DiPaula BA, Menachery E. Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients. J Am Pharm Assoc. 2015;55(2):187–92. doi:10.1331/JAPhA.2015.14177.
   Google Scholar
• Pals H, Bratberg J. Improving access to care via psychiatric clinical pharmacist practitioner collaborative management of buprenorphine for opioid use disorder. J Am Pharm Assoc. 2022;62(4):1422–9. doi:10.1016/j.japh.2022.03.006.
   Google Scholar
• Wu L-T, John WS, Ghitza UE, Wahle A, Matthews AG, Lewis M, Hart B, Hubbard Z, Bowlby LA, Greenblatt LH, et al. Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network. Addiction. 2021;116(7):1805–16. doi:10.1111/add.15353.
   PubMed Web of Science ®Google Scholar
• Green TC, Serafinski R, Clark SA, Rich JD, Bratberg J. Physician-delegated unobserved induction with buprenorphine in pharmacies. N Engl J Med. 2023;388(2):185–6. doi:10.1056/NEJMc2208055.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Fentanyl Test Strips: A Harm Reduction Strategy. https://www.cdc.gov/stopoverdose/fentanyl/fentanyl-test-strips.html#print. Accessed January 17, 2023.
   Google Scholar
• Goldman JE, Waye KM, Periera KA, Krieger MS, Yedinak JL, Marshall BDL. Perspectives on rapid fentanyl test strips as a harm reduction practice among young adults who use drugs: a qualitative study. Harm Reduct J. 2019;16(1):3. doi:10.1186/s12954-018-0276-0.
   PubMedGoogle Scholar
• Vidourek RA, King KA, Yockey RA, Becker KJ, Merianos AL. Straight to the point: a systematic review of needle exchange programs in the United States. J Behav Health. 2019;10(0):1. doi:10.5455/jbh.20181023074620.
   Google Scholar
• United States Food and Drug Administration (FDA). FDA Approves First Over-the-Counter Naloxone Nasal Spray. March 29, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-over-counter-naloxone-nasal-spray. Accessed June 19, 2023.
   Google Scholar
• Smart R, Pardo B, Davis CS. Systematic review of the emerging literature on the effectiveness of naloxone access laws in the United States. Addiction. 2021;116(1):6–17. doi:10.1111/add.15163.
   PubMed Web of Science ®Google Scholar
• France CP, Ahern GP, Averick S, Disney A, Enright HA, Esmaeli-Azad B, Federico A, Gerak LR, Husbands SM, Kolber B, et al. Countermeasures for preventing and treating opioid overdose. Clin Pharmacol Ther. 2021;109(3):578–90. doi:10.1002/cpt.2098.
   PubMed Web of Science ®Google Scholar
• Edinoff AN, Nix CA, Reed TD, Bozner EM, Alvarez MR, Fuller MC, Anwar F, Cornett EM, Kaye AM, Kaye AD, et al. Pharmacologic and clinical considerations of nalmefene, a long duration opioid antagonist, in opioid overdose. Psychiatry Int. 2021;2(4):365–78. doi:10.3390/psychiatryint2040028.
   Google Scholar
• Thakrar AP, Alexander GC, Saloner B. Trends in buprenorphine use in US jails and prisons from 2016 to 2021. JAMA Netw Open. 2021;4(12):e2138807. doi:10.1001/jamanetworkopen.2021.38807.
   PubMed Web of Science ®Google Scholar
• Hirai AH, Ko JY, Owens PL, Stocks C, Patrick SW. Neonatal abstinence syndrome and maternal opioid-related diagnoses in the US, 2010-2017. JAMA. 2021;325(2):146–55. doi:10.1001/jama.2020.24991.
   PubMed Web of Science ®Google Scholar
• Committee on Obstetric Practice. ACOG committee opinion no. 711. Opioid use and opioid use disorder in pregnancy. Opioid Gynecol. 2017;130:e81–e94.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. A Collaborative Approach to the Treatment of Pregnant Women with Opioid Use Disorders. HHS Publication No. (SMA) 16-4978. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2016. https://ncsacw.acf.hhs.gov/files/Collaborative_Approach_508.pdf. Accessed January 26, 2023.
   Google Scholar
• Link HM, Jones H, Miller L, Kaltenbach K, Seligman N. Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis. Am J Obstet Gynecol MFM. 2020;2(3):100179. doi:10.1016/j.ajogmf.2020.100179.
   PubMed Web of Science ®Google Scholar
• Guttmacher Institute. Substance use during pregnancy. https://www.guttmacher.org/state-policy/explore/substance-use-during-pregnancy. Accessed January 28, 2023.
   Google Scholar
• Rizk AH, Simonsen SE, Roberts L, Taylor-Swanson L, Lemoine JB, Smid M. Maternity care for pregnant women with opioid use disorder: a review. J Midwifery Womens Health. 2019;64(5):532–44. doi:10.1111/jmwh.13019.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants. HHS Publication No. (SMA) 18-5054. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2018. https://store.samhsa.gov/sites/default/files/d7/priv/sma18-5054.pdf. Accessed January 30, 2023.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. Screening and Treatment of Substance Use Disorders among Adolescents. Advisory. Publication No. PEP20-06-04-008; 2021. https://store.samhsa.gov/sites/default/files/pep20-06-04-008.pdf. Accessed January 16, 2023.
   Google Scholar
• Robinson CA, Wilson JD. Management of opioid misuse and opioid use disorders among youth. Pediatrics. 2020;145(Suppl 2):S153–S164. doi:10.1542/peds.2019-2056C.
   PubMedGoogle Scholar
• The Society for Adolescent Health and Medicine. Medication for adolescents and young adults with opioid use disorder. J Adolesc Health. 2021;68(3):632–6.
   PubMed Web of Science ®Google Scholar
• Mitchell SG, Monico LB, Gryczynski J, Fishman MJ, O'Grady KE, Schwartz RP. Extended-release naltrexone for youth with opioid use disorder. J Subst Abuse Treat. 2021;130:108407. doi:10.1016/j.jsat.2021.108407.
   PubMed Web of Science ®Google Scholar
• Alinsky HR, Hadland ES, Matson AP, Cerda M, Saloner B. Adolescent-serving addiction treatment ­facilities in the united states and the availability of medications for opioid use disorder. J Adolesc Health. 2020;67(4):542–9. doi:10.1016/j.jadohealth.2020.03.005.
   PubMed Web of Science ®Google Scholar
• DEA Announces Important Change to Registration Requirement. https://www.deadiversion.usdoj.gov/pubs/docs/A-23-0020-Dear-Registrant-Letter-Signed.pdf. Accessed January 25, 2023.
   Google Scholar